Clinical trial
PPAR - Combination With Metformin
NCT00162240 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00162240 |
|---|---|
| Title | PPAR - Combination With Metformin |
| Official title | A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Metformin Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Muraglitazar |
| Enrollment | 534 |
| Start date | Jun 1, 2003 |
| Completion | May 1, 2004 |
| First posted | Sep 13, 2005 |
| Last update posted | Apr 27, 2012 |
| Countries | Argentina, Australia, Brazil, Canada, France, Mexico, Peru, Puerto Rico, South Korea, Sweden, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: